AstraZeneca Pharma, Abbott Healthcare terminate distribution agreements for diabetes drug in India

AstraZeneca India will continue to independently market Dapagliflozin, the combinations of Dapagliflozin and Metformin as well as Dapagliflozin and Saxagliptin in India under the brand names Forxiga, Xigduo and Qtern respectively, the filing said.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3wC75KU
via IFTTT